Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: The aim of this study was to verify the predictors of recurrence and survival in lung adenocarcinoma patients with experiences of breast cancer therapies. METHODS: We retrospectively reviewed consecutive patients who were treated at our hospital for lung adenocarcinoma from 2004/01 to 2014/03. The patients were divided into groups of those with lung adenocarcinoma alone and those with lung and breast cancer. Kaplan-Meier plots and log-rank tests were used to estimate outcomes. RESULTS: 54 patients with lung adenocarcinoma and breast cancer were compared with 457 patients with single primary lung adenocarcinomas. After propensity score matching with control of age, operation type, smoking status and pathologic stage, tumor differentiation, recurrence rate and tumor size were significantly different between two groups. The significant predictors for recurrence included undergone chemotherapy (HR = 25, p 

Original publication

DOI

10.1007/s00432-020-03162-5

Type

Journal article

Journal

J Cancer Res Clin Oncol

Publication Date

05/2020

Volume

146

Pages

1299 - 1306

Keywords

Breast cancer, Epidermal growth factor receptor, Lung adenocarcinoma, Adenocarcinoma of Lung, Breast Neoplasms, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms, Neoplasm Recurrence, Local, Neoplasms, Second Primary, Prognosis, Propensity Score, Receptor, ErbB-2, Registries, Retrospective Studies, Risk, Taiwan